New York Personal Injury Law Blog » Personal Injury Law Round-Up

 

November 16th, 2007

Personal Injury Law Round-Up – Final Edition

The New York Personal Injury Law Blog presents the final edition of the Personal Injury Law Round-Up, as a couple of changes are being made as I hit my first year anniversary…

We’ll start with the issue of tort “reform”:

In a resounding victory for patients, an Illinois court found that a tort “reform” damages cap is an unconstitutional violation of due process and equal protection by artificially limiting what medical malpractice victims can receive for their pain and suffering. Mark McKenna has more with a link to the decision; And Justinian Lane at TortDeform explains that the failure of this “reform” made no difference for an insurer’s decision to stay in the state;

[Edit – 11/19/07: In an email to me, Robert Peck of the Center for Constitutional Litigation, who argued the case, alerted me that the decision was ruled unconstitutional based solely on separation of powers issues. It was therefore unnecessary to reach the other issues.]

John Day gives some statistics from Tennessee on medical malpractice suits, settlements and more, in the context of why further tort “reform” is not necessary;

Ron Miller discusses how non-economic damage caps may be considered discriminatory toward women;

Justinian Lane at TortDeform follows the Texas story of tort “reform,” to find out who benefited, and who didn’t;

At TortsProf, guest blogger Chris Robinette discusses the efforts in Arizona to kill off as many emergency room negligence cases as they can by raising the standard of proof to “clear and convincing evidence;”

Kanye West’s mother died during cosmetic surgery in California, and Hans Poppe wants to know if he would be able to find a medical malpractice lawyer to investigate if he wanted to because, you guessed it, tort “reform” that caps damages;

Also at TortsProf, Robinette finds a notebook from a student of William Prosser (Prosser on Torts) has surfaced, with some of the legendary professor’s thoughts.

And into litigation:

Not in suit yet, but…Nine children were hospitalized after eating Aqua Dots that used a toxic glue, according to The Consumerist. The product came from China, naturally.

John Day and on the discoverability of insurance policy limits (which is standard disclosure in New York);

Bill Childs on a suit against the KKK for the beating of a man, with the announced purpose of putting the Klan out of business;

Bill Marler discusses the lame excuses Cargill is giving for distributing contaminated beef;

From the land of settlements: Drug and Device Law has more on the Vioxx settlement and expands upon a subject I mentioned in my marathon Blawg Review #134 (discussed just after the 21 mile point), that being the impact of those that choose not to settle, which are likely to be the more substantial cases. And as Ed Silverman points out at Pharmalot, the settlement is only for U.S. claimants. Ted Frank has a good round up of analysis on the potential problems spots at Point of Law; And Howard Erichson reports on a plaintiffs-only conference to discuss the settlement;

From the miscellaneous category: New York State practitioners should take note of a reversal in Raffellini v. State Farm regarding the issue of whether a “serious injury” threshold applies to supplemental insurance. No Fault Paradise has the scoop;

And finally:

(Eric Turkewitz is a personal injury attorney in New York)

Links to this post:

turkewitz rounds up tort “reform”
eric turkewitz’s weekly round-up on ny personal injury law blog includes the latest on tort “reform” on the web. check it out. browse the links to the other blog posts–they’re worth it–as i’m certain you’ve already read and thoroughly
posted by Kia Franklin @ November 16, 2007 12:03 PM

One thought on “Personal Injury Law Round-Up – Final Edition

  1. Should there be a ROUND 2?
    What about alleged bone/spine healing problems?

    Many people criticize most, or all of the Merck/Vioxx claimants, feel that Merck just did no wrong, and is as pure as the driven snow. There is also a good deal of whining that the settlement dollars could have been used for R&D). Some interesting research that one may wish to do, whether you are positive or negative about the agreement is to start Googling on are terms such as:

    vioxx bone spine healing
    cox-2 bone spine healing
    fracture bone spine healing Vioxx

    and remember this:

    1 there are (per year!) hundreds of thousands of broken bones, spine injuries, ortho. operations, etc.

    2 with the sales of Vioxx having been so high, it is not hard to interpolate tens of thousands of individuals have been very negatively impacted by Vioxx and they don’t even know how it might (allegedly) have happened! Furthermore, considering there is still a cox-2 inhibitor on the market (Celebrex); AND others drugs in the same class have attempted to get to the market (ARCOXCIA/Merck; PREXIGE/Novartis) which would seem likely to attempt again as the Vioxx settlement works its way through..

    For the record I definitely support the agreement. On the whole and at first view it looks reasonable. I understand it must strike a balance between the very strong cases and the very weak ones certainly many cases have a low value, and Merck does have to protect itself from providing unjust reward amounts. However, I do hope that this does not come at the expense of the strong cases. It is a difficult walk to balance. Hopefully there are mechanisms to facilitate fairness in distribution it is too early to understand. It is up to the people to now vote, and let the chips fall where they may!

    However, interesting food for thought on the timing of the agreement: the results of several years of work by the PSC within the MDL process was apparently about one month away from making the PSC MDL Trial Package generally available for the trial attorneys to use as their cases were to be remanded back to the states from which they came. Thus, hundreds, perhaps thousands of Vioxx lawsuits were about to be launched along with the publicity, etc.

    I also support what I would like to call VIOXX Round 2.

    Just one Independent Research (IR) snippet – more follow: there are hundreds representing many studies PLUS a quite logical analysis of the bone/spine healing process by so many well respected surgeons, physicians, researchers, etc.

    In fact, the 2003 Merck Manual very well describes the healing process certainly a good enough description to logically assume that they (Merck) allegedly would (and should) have been at least wary of the cox-2 inhibitors! I may be wrong; but it seems that the Merck description of the bone/healing process seems to have worked its way out of the manual if I am right, seems like interesting timing

    Just one of the hundreds of Google “hits” that may be of interest

    MAY 21, 2002 – JOURNAL OF BONE AND MINERAL RESEARCH – COX-2 DECREASES BONE HEALING? – mechanical testing revealed that COX-2 inhibitors reduce bone strength ((in healing) note by this BLOG’s author) expression of COX-2 is critical for bone healing essential for fracture healing the inhibition of prostaglandin synthesis stops normal fracture healing;

    You will continue to find Research, and scientific description that (allegedly) another, very significant problem of Vioxx existed (bone/spine healing) and was (allegedly) known (and certainly should have been known) by Merck. Unfortunately for the public Merck has (allegedly) successfully swept the issue(s) under the rug and radar; with severe consequences for many people, but with many benefits (allegedly) for Merck.

    I allege that the responsible action would have been to announce the bone/spine concerns when Vioxx was taken off the market. (Allegedly) Merck knew, or should have known, enough to have at least more than a passing interest in the problem and should have taken a postion. Instead, this muddy picture,” (as termed by Dr. Scott Reuben of Baystate Medical Center in Springfield, Mass.; and of which one of my own surgeons referred to in a similar way, was allegedly maintained by Merck rather than provide any kind of caution, warning(s), consumer or physician education, etc. Nope this was one issue that apparently and allegedly was better just to keep muddy as long as possible delay creates confusion and allows red herrings to become a strategic tool for profits One red herring example many studies were done on animals – sure that does not (by itself) correlate directly into human problems however there is enough other evidence, research and very well understood scientific explanations of the bone/spine healing process (including the 2003 Merck Manual) that there is enough evidence converging to at least raise a healthy convergence that just should not have been ignored. Furthermore, and get this, it (allegedly) seems that Merck also used animal studies to justify many of the benefits (and potential ones) of Vioxx. So, which is it? do animal studies have justification or don’t they? You may hear another red herring that it would not be ethical to conduct human experiments. There are, of course, other ways to predict the impact on humans (controlled studies of people who have already broken a bone, for example). Now that I have been off of Vioxx since the day of withdrawal, perhaps I can offer to have a broken bone or two (but not a major bone this time! and in a controlled manner) in the name of science and Public Awareness.

    I still have hope that the Public will demand that Merck acknowledge the (alleged) bone/spine healing issues, NOW, and that the STATUTE OF LIMITATIONS clock be reset for potential bone/spine litigants. Because this was not done, Merck (allegedly) most likely avoided many (thousands) more lawsuits. This also would have made their general publicity much worse, and perhaps juries would have seen (allegedly) not one, but a pattern of alleged deceit by active concealment, as well as the other charges. If this had happened, the value of the heart/cv/stroke “settlement” quite likely would have been higher. But lets get back to the bone/spine (alleged) problems ROUND 2.

    I believe that I have become very well versed and researched on many of the issues as I continue to pursue my own, litigation (attorneys ONLY wanted to take cases which were heart/CV/stroke oriented – I better not get started on that subject also but I have come to understand why and its not what you will be told…). I tried to have the public, and attorneys across the land, become aware of the bone/spine healing problems, but with limited success. After all – it has been much easier and offers much less risk submitting a lawsuit and letting the MDL do the heavy lifting Discovery of common issues, than actually conduct a jury trial, along with its own Discovery process. As of yet, I have not reached the critical mass (of Public awareness) needed for logical and responsible actions to be put into motion (i.e. Merck Round 2). I still hope to do so, and consider this another attempt at Public Awareness.

    How about this idea if indeed the settlement is approved with its 85% threshold, the legal community (esp. the Plaintiffs BAR) should now tackle the bone/spine alleged problems. The issues are very are real, there is plenty of evidence, and perhaps the causation issues are more direct to deal with. At least, for gosh sake, a real investigation by the Plaintiffs BAR as to whether or not it should pursue bone/spine litigation, and push to have the STATUTE OF LIMITATIONS extended should be a very high priority. And while they are at it, perhaps it is appropriate for another review of Celebrex (another Cox-2 inhibitor) along the same lines.

    As mentioned above, perhaps tens of thousands) people, in the past (Vioxx) and CURRENTLY (Celebrex), were (are) being adversely impacted. It is about time that both Merck (and Pfizer/Celebrex) finally takes a comprehensive, cohesive, position on Cox-2 inhibitors as well as the potential negative synergies with emerging (alleged) issues and litigation with bio-phosphates, such as FOSAMAX. I, personally, would shutter at taking a Cox-2 inhibitor and something like FOSAMAX concurrently especially since FOSAMAX can stay in the bones for about 10 years. This is quite possibly an explosive issue that should be addressed now, not later after the (potential) massive damage. A little bit of “preventive medicine is certainly due here and wouldnt you think that Merck and Pfizer (and by the way Novartis), being the “bone experts should have already have had position(s) on this?. Also, though any degree of reasonableness and safety concerns would have called for post-marketing monitoring. Why should these companies have to be ordered for monitoring. My gosh, it is only common sense and what you would expect of world class organizations!

    Back to Vioxx, just a small sample of the Independent Research (IR) that Merck (allegedly) just simply ignored and (allegedly) apparently hoped would just fade away. By the way, (allegedly) there were NO warnings, nor public or physician education on the bone/spine healing issue(s) there were, and are, other factors that should have caused responsible actions but allegedly failed to – thus the issue(s) would remain in never never land! It certainly would seem that even just the general industry wariness (of Cox-1 inhibitor concerns) SHOULD have motivated Merck to address the matter with Vioxx (as well as its new proposed Cox-2 inhibitor entry Arcoxia). Wouldnt you think that they would be the SUBJECT MATTER EXPERTS! There seems to be no reasonable explanation as to why Merck did not tackle the mounting Independent Research (IR), the very scientific explanations, and general industry wariness of early generation of Cox-1 inhibitors (which also, by the way, were(allegedly) not treated in an open or fair manner.

    REPRINTED FROM: http://WWW.USATODAY.COM/NEWS – “It’s time to tell the public,” concludes Dr. Thomas Einhorn, Boston University’s orthopedic surgery chairman (Einhorn, A PAID CONSULTANT for Vioxx maker Merck & Co. and Celebrex maker Pharmacia Corp). New research suggests some of the most widely used painkillers may delay healing of a broken bone “If it were my fracture … to me every day counts,” he says. Vioxx and Celebrex are among the culprits. the makers of Vioxx and Celebrex deny any link. Comment by author a paid consultants for Merck and Pharmacia (at the time) is apparently not even followed up. apparently his results were not what they wanted to see

    Copyright 2002 The Associated Press. All rights reserved. O’Connor says his findings prompted some colleagues to withhold cox-2 inhibitors from broken-bone patients Arthritis Foundation urges more research… surgeons made the surprise discovery a few years ago that high doses of the intravenous NSAID Toradol delays spinal surgery healing a recent British study concluded using NSAIDS was the biggest factor in delayed healing of a broken leg. “It is confusing. … You see this muddy picture,” says Dr. Scott Reuben of Baystate Medical Center in Springfield, Mass., who conducted that study — and calls for targeted research on broken-bone sufferers It’s an important question, as more Americans regularly use Vioxx, Celebrex and other anti-inflammatory painkillers called NSAIDS Doctors increasingly offer bone surgery or fracture patients higher and higher doses of such painkillers in place of narcotics At issue is the discovery that an enzyme called cox-2, which causes pain and inflammation, also appears to play a crucial role in bone healing. Einhorn, a paid consultant for Vioxx maker Merck & Co. and Celebrex maker Pharmacia Corp (at the time) despite the companies displeasure concludes “a prudent approach” is to temporarily quit using either NSAIDS, Vioxx or Celebrex if you break a bone.

    “If you don’t know, you should err on the side of caution.” – my comment apparently and allegedly, Merck decided not to err on the side of caution!

    COX-2: WHERE ARE WE IN 2003? – THE ROLE OF CYCLOOXYGENASE-2 IN BONE REPAIR – EINHORN TA. PROFESSOR AND CHAIRMAN, DEPARTMENT OF ORTHOPEDIC SURGERY, BOSTON UNIVERSITY MEDICAL CENTER, BOSTON, MASSACHUSETTS – both non-specific and specific inhibitors of cyclooxygenases impair fracture healing – but that this is due to the inhibition of Cox-2 and not COX-1! Vioxx is a Cox-2 inhibitor. “It’s time to tell the public,” concludes Dr. Thomas Einhorn;

    Somehow, this study flew under the radar,” SAYS JASON THEODOSAKIS, MD, MS, MPH., AUTHOR OF THE ARTHRITIS CURE (ST. MARTINS PRESS 2004). This information is unlikely to be broadcast by pharmaceutical companies, he explains: It could affect the billions of dollars in sales of the COX-2 inhibitors if people knew they might be destroying cartilage while theyre trying to relieve their pain.

    FEBRUARY 02, 2005 – HSS PHYSICIANS REVIEW LITERATURE ON THE SAFETY OF COX-2 INHIBITORS – COX-2 inhibitors effect fracture healing and spine fusion should never be used in spinal fusion;

    The unnecessary victimized (including myself!) who’s bones and/or spines didn’t heal correctly, or even at all, never even knew what hit them! We didnt even have a warning not even a chance to make an informed decision. Certainly I would have not taken Vioxx if I were to at least have been warned! Especially sad is that the period in question generally revolves around the first three or four weeks of healing not really a very long time.

    POSSIBLE OTHER PUBLIC CONCERNS
    VIOXX, and all COX-2 inhibitor drugs, work by inhibiting the body’s natural response to inflammation and bone repair/regeneration. It begs other questions. (1) What might be the impact of FOSAMAX (also produced by Merck!) on bone healing? It has already been alleged, and there are lawsuits pending, that it can prevent the jaw from healing after a tooth extraction (bone dies – the issue is called Dead Jaw). (2) This should cause one to question – what about FOSAMAX’s relation to other bones? (3) Furthermore, what if some one took VIOXX, or another Cox-2 inhibitor, and FOSAMAX at the same time? Since both work basically by interfering with the bodys natural reaction of bone repair and healthy regeneration – could the problem be even worse with concurrent use which did and does exist?

    Also, what other bone problems may develop with the past- concurrent (Cox-2 inhibitor VIOXX and FOSAMAX USAGE?) Incredibly, both drugs are/were produced by Merck! Shouldnt Merck (allegedly) have a formal opinion on this by now, as well as some kind of testing and Post Marketing follow-up? Also, since Celebrex exists today and it is also a Cox-2 inhibitor, what about current concurrent use (Celebrex and Fosamax)? Shouldnt the maker of Celebrex (allegedly) also have a formal opinion about this, as well as some kind of testing and Post Marketing follow-up?

    If you would like to review more of Mr. Harrisons history and gain more thoughts on your situation if similar, please visit the blog – http://badbonehealing.wordpress.com/. The blog is quite aged, but it provides insight to what may represent many other severe cases (obviously there is a range).

    Yes – do some research as suggested above; and those of you who are critical of the claimants; perhaps you might realize that things are not so simple. Perhaps you might feel as I, that (allegedly and potentially) a pattern of deceit by omission is emerging and had the Vioxx lawsuit been worked that way, things might have been worse for Merck. Perhaps you will realize that it is quite likely many, many of the claimants have good cause.

    Some mention, vehemently, that R&D investments could have been made instead of compensating the claimants. Yes, R&D is essential to maintain profits AND serve the public interest by contributing to the publics health. At the same time, punishing a company that has (allegedly) received ill-gotten gains is also essential and ALSO serves the public interest and the publics health. Should a minority of victims be sacrificed, without even compensation for the (unknowing and uninformed sacrifice), in the name of maximizing Mercks R&D? Furthermore, in the long run the restitution by Merck actually does contribute to profit, as any company harming the public time and time again will not survive in that long run. Consider it like a boat unless the minor corrections are made and the ships crew learns how to steer correctly (i.e. learns that you cannot run roughshod over unsuspecting victims), as early as possible, the ship will drift even further off course until it is hopelessly drifting and forever lost (i.e. gone out of business). If Merck were not set straight by the legal and market forces, it will not survive the free market of which it must abide by those same legal and market forces. Whats the alternative anarchy so that R&D can be maximized for the sake of maximizing it?

    And remember when you see a person, (allegedly) deformed from using Vioxx during bone/spine healing….

    “there but for the Grace of God, go I”…..

    Dennis Harrison
    Catskill, NY